Retatrutide

Overview

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly and Company that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tri-agonist approach extends the dual-agonist concept pioneered by tirzepatide by adding glucagon receptor activation — a strategy that leverages glucagon's ability to increase energy expenditure and promote hepatic fat oxidation, potentially addressing limitations of existing incretin-based therapies.

Retatrutide entered clinical development in the early 2020s and generated substantial attention following the publication of Phase 2 trial results in 2023, which demonstrated mean weight loss of approximately 24% at the highest dose — the largest reduction reported for any pharmaceutical agent in a controlled trial at that time. Phase 3 trials (the TRIUMPH program) were initiated to evaluate retatrutide across multiple metabolic indications including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH).

The compound represents an evolution of the incretin-based therapeutic strategy from single agonism (liraglutide, semaglutide) through dual agonism (tirzepatide) to triple agonism, each generation incorporating additional metabolic pathways to achieve progressively greater efficacy. This progression exemplifies the drug development pipeline in metabolic disease.

Structure and Sequence

Retatrutide is a 39-amino-acid peptide engineered to activate three distinct receptors with carefully balanced potency:

• Molecular weight: Approximately 4,700 g/mol
• Base template: Modified GIP sequence, similar to tirzepatide, with additional modifications to confer glucagon receptor activity
• Key structural features:
  • Position 2: Aib (alpha-aminoisobutyric acid) substitution for DPP-4 resistance
  • Fatty acid acylation: C20 fatty diacid chain attached via a linker at Lys20, enabling albumin binding for once-weekly pharmacokinetics
  • Multiple amino acid substitutions throughout the sequence to balance agonist activity across all three receptors
  • C-terminal amidation for metabolic stability

Receptor affinity profile:

• GIP receptor: Full agonist with high potency
• GLP-1 receptor: Agonist activity, somewhat lower relative potency compared to dedicated GLP-1 agonists
• Glucagon receptor: Partial to full agonist — the distinguishing feature that separates retatrutide from tirzepatide

The inclusion of glucagon receptor agonism required careful dose optimization. Glucagon promotes hepatic glucose output, which could theoretically worsen glycemic control. However, the counterbalancing effects of GLP-1 and GIP receptor activation on insulin secretion appear to maintain or improve net glycemic control while capturing glucagon's metabolic benefits.

Mechanism of Action

Triple Receptor Activation

GLP-1 Receptor Agonism:

• Glucose-dependent insulin secretion from pancreatic beta cells
• Suppression of inappropriate glucagon release during hyperglycemia
• Central appetite suppression via hypothalamic and brainstem GLP-1R activation
• Delayed gastric emptying, contributing to postprandial satiety

GIP Receptor Agonism:

• Complementary insulinotropic effects, particularly in the postprandial state
• Direct effects on adipose tissue metabolism, potentially improving fat handling and insulin sensitivity
• Central effects on energy balance through hypothalamic GIP receptors
• Potential bone-protective effects via osteoblast GIP receptor activation

Glucagon Receptor Agonism (the distinguishing pathway):

• Increased energy expenditure: Glucagon activates thermogenesis in brown adipose tissue and increases hepatic energy consumption, potentially addressing the metabolic adaptation (reduced resting energy expenditure) that limits weight loss with other agents
• Hepatic lipid oxidation: Glucagon promotes fatty acid beta-oxidation in the liver, which may be particularly relevant for reducing hepatic steatosis in MASH
• Amino acid catabolism: Glucagon stimulates amino acid turnover and ureagenesis, contributing to overall energy expenditure
• Lipolysis: Glucagon promotes adipose tissue lipolysis, mobilizing fat stores for energy production

Integrated Metabolic Effects

The triple-agonist design creates a metabolic profile in which:

• Appetite is reduced (GLP-1 and GIP centrally)
• Insulin secretion is enhanced in a glucose-dependent manner (GLP-1 and GIP)
• Energy expenditure is increased (glucagon)
• Hepatic fat is reduced through oxidation (glucagon) and reduced lipogenesis (insulin sensitization)
• The hyperglycemic risk of glucagon is offset by the insulinotropic effects of GLP-1 and GIP

This "metabolic triad" approach potentially addresses one of the key limitations of pure GLP-1 agonism — that weight loss occurs primarily through caloric restriction (appetite suppression) rather than through increased energy expenditure.

Research Summary

Pharmacokinetics

• Half-life: Approximately 6 days, supporting once-weekly subcutaneous dosing
• Administration: Once-weekly subcutaneous injection
• Dose titration: Gradual escalation over multiple weeks to mitigate gastrointestinal adverse effects (similar approach to tirzepatide and semaglutide)
• Protein binding: Extensive albumin binding via C20 fatty diacid modification
• Steady state: Reached within approximately 4-5 weeks of consistent weekly dosing
• Metabolism: Expected endogenous peptide degradation pathways; detailed human pharmacokinetic characterization is ongoing through Phase 3 trials
• Dose range in trials: 0.5 mg to 12 mg weekly in Phase 2; Phase 3 doses to be determined based on dose-optimization data

Dosing Protocols

Retatrutide is an investigational compound currently in Phase 3 clinical trials (TRIUMPH program). No FDA-approved dosing exists. The following reflects the Phase 2 trial design.

Phase 2 Trial Titration Schedule

Key Points

• Route: Subcutaneous injection, once weekly
• Titration: Gradual dose escalation over 8–12 weeks to mitigate GI side effects
• Maximum studied dose: 12 mg weekly (Phase 2)
• Timing: Same day each week
• Phase 2 results: 24.2% mean weight loss at 12 mg dose over 48 weeks
• Common side effects: Nausea, diarrhea, vomiting — similar to other incretin agonists, mitigated by titration
• Status: Phase 3 doses to be confirmed based on dose-optimization data from the TRIUMPH program

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Titration Schedule

Cycle Guidelines

• Minimum treatment duration: 24 weeks (clinical trials ran 36-48 weeks)
• Route: Subcutaneous injection, once weekly
• Timing: Same day each week; rotate injection sites
• Injection sites: Rotate between abdomen, thighs, and upper arms (injection site rotation)
• Titration: Gradual dose escalation is essential to manage GI side effects (nausea, diarrhea, vomiting)
• Note: Retatrutide is a triple agonist (GIP/GLP-1/glucagon); not yet FDA-approved

Common Discussion Topics

Comparison to tirzepatide: The central question is whether the addition of glucagon agonism produces clinically meaningful advantages over the dual GIP/GLP-1 agonism of tirzepatide. Phase 2 data suggest greater absolute weight loss (24% versus 22.5% at comparable timepoints), and the energy expenditure component could theoretically improve weight loss maintenance. Head-to-head trial data will be needed for definitive comparison.

Glucagon paradox: The inclusion of a glucagon agonist in a diabetes/obesity drug initially appears counterintuitive, given that glucagon raises blood glucose. The resolution lies in the balanced polypharmacology — GLP-1 and GIP receptor activation provide sufficient insulinotropic counterbalance to maintain glycemic control while allowing the metabolic benefits of glucagon to manifest.

MASH therapeutic potential: Retatrutide's dramatic liver fat reduction (approximately 86% relative reduction in Phase 2) positions it as a potentially transformative MASH therapy. Glucagon-driven hepatic fat oxidation, combined with weight loss-mediated reductions in hepatic lipid delivery, may produce superior liver outcomes compared to existing approaches.

Weight loss sustainability: A key question is whether the energy expenditure component of glucagon agonism helps maintain weight loss over the long term by partially counteracting the metabolic adaptation that drives weight regain after caloric restriction alone.

Safety monitoring in Phase 3: Areas of particular surveillance include bone mineral density (glucagon may promote bone resorption), lean mass preservation (glucagon promotes amino acid catabolism), and cardiovascular effects (glucagon increases heart rate and cardiac output). The Phase 3 TRIUMPH program is designed to characterize these long-term safety endpoints.

Related Compounds

• Tirzepatide — dual GIP/GLP-1 agonist and the closest comparator
• Semaglutide — single GLP-1 agonist with extensive clinical evidence
• Liraglutide — earlier-generation daily GLP-1 agonist